Unlocking Efficiency and Quality: What is New in Phoenix™ 8.4?
Join us for an exclusive webinar as Certara introduces the highly anticipated version 8.4 of…
CertaraJune 5, 2023
How digital communication tools will revolutionize your medical conversation
Medical Affair, Market Access, and Sales & Marketing teams at most of pharmaceutical companies use…
CertaraApril 24, 2023
Transforming Trial Success: AI’s Role in Clinical Trial Meta-Analysis
Published research and literature-based content holds valuable insight that can inform clinical trial execution and…
CertaraApril 19, 2023
Antibody-drug Conjugates in the Clinic: Key Considerations & the Role of Modeling in Expediting Development
Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a…
CertaraApril 17, 2023
Data-Backed Trial Design– Applying AI to Clinical Outcome Analysis
Global spending on clinical trials is expected to reach $68.9 billion per year by 2025…
CertaraMarch 17, 2023
What you should know about FDA Project Optimus for your oncology drug approval
Historically, the dosing strategy for oncology drugs has focused on the maximum tolerated dose. This…
CertaraMarch 10, 2023
RAPS Sponsored Webcast: Oops, I messed Up! How to Avoid (and Fix) Common Regulatory Submission Mistakes
Oops, I made a mistake! Everyone has made or seen one, and sometimes it is…
CertaraMarch 9, 2023
Learn how to create CDISC domains in minutes with PK Submit
Creating CDISC domains as part of the pharmacokinetic (PK) deliverable for regulatory submissions can be…
CertaraMarch 1, 2023
FDA Modernization Act 2.0 – What does it mean for drug developers?
Historically, the FDA has required drug discovery and development programs to include animal testing. This…
CertaraFebruary 21, 2023
RAPS Sponsored: How Drug Developers Can Navigate the Inflation Reduction Act
The Inflation Reduction Act (enacted in August 2022) contains profound changes for the healthcare and…
CertaraFebruary 10, 2023
